Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr

Aurobindo Pharma Ltd. has reported a marginal dip in its consolidated profit after tax (PAT) to Rs. 903 crore for Q4 FY25 as against Rs. 907 crore in Q4 FY24. The company posted robust topline growth for the quarter ended March 31, 2025 with total revenue from operations increasing to Rs. 8,382 crore as compared to Rs. 7,580 crore in Q4 FY24.

During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore.  Europe formulations revenue increased by 17.2 per cent YoY to Rs. 2,147 crore. Growth Markets revenue decreased by 7.8 per cent YoY to Rs. 786 crore. API revenue increased by 5 per cent to Rs. 1,069 crore. EBITDA before R&D stood at Rs. 2,202 crore with a margin of 26.3 per cent.

For the Financial Year ended March 31, 2025, Aurobindo’s PAT increased 10 per cent YoY to Rs. 3,484 crore from Rs. 3,169 crore in FY24. Annual income also grew by a big margin of Rs. 31,724 crore in FY25 from Rs. 29,002 crore in FY24, up 9.4 per cent.

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio. Our European operations continue to perform exceptionally well, moving steadily towards the $1 billion revenue milestone. Backed by our ongoing capacity enhancements we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders.”